Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study

Hiroya Utsumi; Makoto Iwata; Naohito Yamaguchi; Yoshihide Sunada; Fumihiko Sakai; Norihiro Suzuki; Nobuo Araki; Imaharu Nakano; Mitsuru Kawamura; Teruo Shimizu; Yukito Shinohara; Hiroya Utsumi; Koichi Hirata; Yasuo Katayama; Tomohiko Mizutani; Akihiko Uchiyama; Toru Mannen; M. Iwata; N. Yamaguchi; Shiori Hashimoto; Masahisa Kodama; Yuko Shimizu; Tatsufumi Murakami; Yutaka Ohsawa; Takahiro Iizuka; Kazushi Takahashi; Shigeru Nogawa; Hidetada Takeda; Takahiro Amano; Toshimasa Yamamoto; Kunio Shimazu; Mitsuya Morita; Ken Ichi Fujimoto; Hidetomo Murakami; Yukihiro Hasegawa; Fumihito Yoshii; Hirohide Takahashi; Hiroo Terashi; Takahide Nagashima; Kunihiko Sakurai; Yoshiaki Kaji; Toshiyuki Kawakami; Norito Kokubun; Yasutoshi Daimon; Hitoshi Kubo; Tetsuya Ishihara; Hiroshi Nagayama; Makoto Hamamoto; Satoshi Kamei; Yutaka Suzuki; Masahiro Sonno

Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study

Hiroya Utsumi, Makoto Iwata, Naohito Yamaguchi, Yoshihide Sunada, Fumihiko Sakai, Norihiro Suzuki, Nobuo Araki, Imaharu Nakano, Mitsuru Kawamura, Teruo Shimizu, Yukito Shinohara, Hiroya Utsumi, Koichi Hirata, Yasuo Katayama, Tomohiko Mizutani, Akihiko Uchiyama, Toru Mannen, M. Iwata, N. Yamaguchi, Shiori HashimotoMasahisa Kodama, Yuko Shimizu, Tatsufumi Murakami, Yutaka Ohsawa, Takahiro Iizuka, Kazushi Takahashi, Shigeru Nogawa, Hidetada Takeda, Takahiro Amano, Toshimasa Yamamoto, Kunio Shimazu, Mitsuya Morita, Ken Ichi Fujimoto, Hidetomo Murakami, Yukihiro Hasegawa, Fumihito Yoshii, Hirohide Takahashi, Hiroo Terashi, Takahide Nagashima, Kunihiko Sakurai, Yoshiaki Kaji, Toshiyuki Kawakami, Norito Kokubun, Yasutoshi Daimon, Hitoshi Kubo, Tetsuya Ishihara, Hiroshi Nagayama, Makoto Hamamoto, Satoshi Kamei, Yutaka Suzuki, Masahiro Sonno

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Several international studies have suggested that treatment of early Parkinsons disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17% and 34% (hazard ratio, 0.57; 95% confidence interval, 0.18-1.81; p = 0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.

Original language	English
Pages (from-to)	163-170
Number of pages	8
Journal	Acta Medica Okayama
Volume	66
Issue number	2
Publication status	Published - 2012
Externally published	Yes

Keywords

Cabergoline
Levodopa
Motor complications
Parkinson's disease

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Cite this

Utsumi, H., Iwata, M., Yamaguchi, N., Sunada, Y., Sakai, F., Suzuki, N., Araki, N., Nakano, I., Kawamura, M., Shimizu, T., Shinohara, Y., Utsumi, H., Hirata, K., Katayama, Y., Mizutani, T., Uchiyama, A., Mannen, T., Iwata, M., Yamaguchi, N., ... Sonno, M. (2012). Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study. Acta Medica Okayama, 66(2), 163-170.

Utsumi, H, Iwata, M, Yamaguchi, N, Sunada, Y, Sakai, F, Suzuki, N, Araki, N, Nakano, I, Kawamura, M, Shimizu, T, Shinohara, Y, Utsumi, H, Hirata, K, Katayama, Y, Mizutani, T, Uchiyama, A, Mannen, T, Iwata, M, Yamaguchi, N, Hashimoto, S, Kodama, M, Shimizu, Y, Murakami, T, Ohsawa, Y, Iizuka, T, Takahashi, K, Nogawa, S, Takeda, H, Amano, T, Yamamoto, T, Shimazu, K, Morita, M, Fujimoto, KI, Murakami, H, Hasegawa, Y, Yoshii, F, Takahashi, H, Terashi, H, Nagashima, T, Sakurai, K, Kaji, Y, Kawakami, T, Kokubun, N, Daimon, Y, Kubo, H, Ishihara, T, Nagayama, H, Hamamoto, M, Kamei, S, Suzuki, Y & Sonno, M 2012, 'Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study', Acta Medica Okayama, vol. 66, no. 2, pp. 163-170.

@article{e597e9f4fb204f31a165f1c5ba114289,

title = "Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study",

abstract = "Several international studies have suggested that treatment of early Parkinsons disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17% and 34% (hazard ratio, 0.57; 95% confidence interval, 0.18-1.81; p = 0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.",

keywords = "Cabergoline, Levodopa, Motor complications, Parkinson's disease",

author = "Hiroya Utsumi and Makoto Iwata and Naohito Yamaguchi and Yoshihide Sunada and Fumihiko Sakai and Norihiro Suzuki and Nobuo Araki and Imaharu Nakano and Mitsuru Kawamura and Teruo Shimizu and Yukito Shinohara and Hiroya Utsumi and Koichi Hirata and Yasuo Katayama and Tomohiko Mizutani and Akihiko Uchiyama and Toru Mannen and M. Iwata and N. Yamaguchi and Shiori Hashimoto and Masahisa Kodama and Yuko Shimizu and Tatsufumi Murakami and Yutaka Ohsawa and Takahiro Iizuka and Kazushi Takahashi and Shigeru Nogawa and Hidetada Takeda and Takahiro Amano and Toshimasa Yamamoto and Kunio Shimazu and Mitsuya Morita and Fujimoto, {Ken Ichi} and Hidetomo Murakami and Yukihiro Hasegawa and Fumihito Yoshii and Hirohide Takahashi and Hiroo Terashi and Takahide Nagashima and Kunihiko Sakurai and Yoshiaki Kaji and Toshiyuki Kawakami and Norito Kokubun and Yasutoshi Daimon and Hitoshi Kubo and Tetsuya Ishihara and Hiroshi Nagayama and Makoto Hamamoto and Satoshi Kamei and Yutaka Suzuki and Masahiro Sonno",

year = "2012",

language = "English",

volume = "66",

pages = "163--170",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "2",

}

TY - JOUR

T1 - Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease

T2 - A 5-year prospective study

AU - Utsumi, Hiroya

AU - Iwata, Makoto

AU - Yamaguchi, Naohito

AU - Sunada, Yoshihide

AU - Sakai, Fumihiko

AU - Suzuki, Norihiro

AU - Araki, Nobuo

AU - Nakano, Imaharu

AU - Kawamura, Mitsuru

AU - Shimizu, Teruo

AU - Shinohara, Yukito

AU - Utsumi, Hiroya

AU - Hirata, Koichi

AU - Katayama, Yasuo

AU - Mizutani, Tomohiko

AU - Uchiyama, Akihiko

AU - Mannen, Toru

AU - Iwata, M.

AU - Yamaguchi, N.

AU - Hashimoto, Shiori

AU - Kodama, Masahisa

AU - Shimizu, Yuko

AU - Murakami, Tatsufumi

AU - Ohsawa, Yutaka

AU - Iizuka, Takahiro

AU - Takahashi, Kazushi

AU - Nogawa, Shigeru

AU - Takeda, Hidetada

AU - Amano, Takahiro

AU - Yamamoto, Toshimasa

AU - Shimazu, Kunio

AU - Morita, Mitsuya

AU - Fujimoto, Ken Ichi

AU - Murakami, Hidetomo

AU - Hasegawa, Yukihiro

AU - Yoshii, Fumihito

AU - Takahashi, Hirohide

AU - Terashi, Hiroo

AU - Nagashima, Takahide

AU - Sakurai, Kunihiko

AU - Kaji, Yoshiaki

AU - Kawakami, Toshiyuki

AU - Kokubun, Norito

AU - Daimon, Yasutoshi

AU - Kubo, Hitoshi

AU - Ishihara, Tetsuya

AU - Nagayama, Hiroshi

AU - Hamamoto, Makoto

AU - Kamei, Satoshi

AU - Suzuki, Yutaka

AU - Sonno, Masahiro

PY - 2012

Y1 - 2012

N2 - Several international studies have suggested that treatment of early Parkinsons disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17% and 34% (hazard ratio, 0.57; 95% confidence interval, 0.18-1.81; p = 0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.

AB - Several international studies have suggested that treatment of early Parkinsons disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17% and 34% (hazard ratio, 0.57; 95% confidence interval, 0.18-1.81; p = 0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.

KW - Cabergoline

KW - Levodopa

KW - Motor complications

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84864761113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864761113&partnerID=8YFLogxK

M3 - Article

C2 - 22525474

AN - SCOPUS:84864761113

SN - 0386-300X

VL - 66

SP - 163

EP - 170

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 2

ER -

Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this